1-20 of 29
Henry S. Friedman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination

Kristen A. Batich, Elizabeth A. Reap, Gary E. Archer, Luis Sanchez-Perez, Smita K. Nair, Robert J. Schmittling, Pam Norberg, Weihua Xie, James E. Herndon, II, Patrick Healy, Roger E. McLendon, Allan H. Friedman, Henry S. Friedman, Darell Bigner, Gordana Vlahovic, Duane A. Mitchell, John H. Sampson
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (8): 1898–1909.
https://doi.org/10.1158/1078-0432.CCR-16-2057
Published: 13 April 2017
View article titled, Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination
Open the PDF for Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination in another window
Includes: Supplementary data
Journal Articles

The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide, and Irinotecan for Newly Diagnosed Glioblastoma

James J. Vredenburgh, Annick Desjardins, David A. Reardon, Katherine B. Peters, James E. Herndon, II, Jennifer Marcello, John P. Kirkpatrick, John H. Sampson, Leighann Bailey, Stevie Threatt, Allan H. Friedman, Darell D. Bigner, Henry S. Friedman
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (12): 4119–4124.
https://doi.org/10.1158/1078-0432.CCR-11-0120
Published: 15 June 2011
View article titled, The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide, and Irinotecan for Newly Diagnosed Glioblastoma
Open the PDF for The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide, and Irinotecan for Newly Diagnosed Glioblastoma in another window
Journal Articles

Phase II Trial of Gliadel plus O6-Benzylguanine in Adults with Recurrent Glioblastoma Multiforme

Jennifer A. Quinn, Sara Xiaoyin Jiang, James Carter, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Jeremy N. Rich, Sridharan Gururangan, Allan H. Friedman, Darell D. Bigner, John H. Sampson, Roger E. McLendon, James E. Herndon, II, Stevie Threatt, Henry S. Friedman
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (3): 1064–1068.
https://doi.org/10.1158/1078-0432.CCR-08-2130
Published: 02 February 2009
View article titled, Phase II Trial of Gliadel plus <em>O</em><sup>6</sup>-Benzylguanine in Adults with Recurrent Glioblastoma Multiforme
Open the PDF for Phase II Trial of Gliadel plus <em>O</em><sup>6</sup>-Benzylguanine in Adults with Recurrent Glioblastoma Multiforme in another window
Journal Articles

Genomic and Molecular Profiling Predicts Response to Temozolomide in Melanoma

Christina K. Augustine, Jin Soo Yoo, Anil Potti, Yasunori Yoshimoto, Patricia A. Zipfel, Henry S. Friedman, Joseph R. Nevins, Francis Ali-Osman, Douglas S. Tyler
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (2): 502–510.
https://doi.org/10.1158/1078-0432.CCR-08-1916
Published: 15 January 2009
View article titled, Genomic and Molecular Profiling Predicts Response to Temozolomide in Melanoma
Open the PDF for Genomic and Molecular Profiling Predicts Response to Temozolomide in Melanoma in another window
Includes: Supplementary data
Journal Articles

Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

Annick Desjardins, David A. Reardon, James E. Herndon, II, Jennifer Marcello, Jennifer A. Quinn, Jeremy N. Rich, Sith Sathornsumetee, Sridharan Gururangan, John Sampson, Leighann Bailey, Darell D. Bigner, Allan H. Friedman, Henry S. Friedman, James J. Vredenburgh
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (21): 7068–7073.
https://doi.org/10.1158/1078-0432.CCR-08-0260
Published: 03 November 2008
View article titled, Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas
Open the PDF for Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas in another window
Includes: Supplementary data
Journal Articles

Mismatch Repair Deficiency Does Not Mediate Clinical Resistance to Temozolomide in Malignant Glioma

Jill A. Maxwell, Stewart P. Johnson, Roger E. McLendon, David W. Lister, Krystle S. Horne, Ahmed Rasheed, Jennifer A. Quinn, Francis Ali-Osman, Allan H. Friedman, Paul L. Modrich, Darell D. Bigner, Henry S. Friedman
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (15): 4859–4868.
https://doi.org/10.1158/1078-0432.CCR-07-4807
Published: 01 August 2008
View article titled, Mismatch Repair Deficiency Does Not Mediate Clinical Resistance to Temozolomide in Malignant Glioma
Open the PDF for Mismatch Repair Deficiency Does Not Mediate Clinical Resistance to Temozolomide in Malignant Glioma in another window
Journal Articles

Molecular Characterization of the Pediatric Preclinical Testing Panel

Geoffrey Neale, Xiaoping Su, Christopher L. Morton, Doris Phelps, Richard Gorlick, Richard B. Lock, C. Patrick Reynolds, John M. Maris, Henry S. Friedman, Jeffrey Dome, Joseph Khoury, Timothy J. Triche, Robert C. Seeger, Richard Gilbertson, Javed Khan, Malcolm A. Smith, Peter J. Houghton
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (14): 4572–4583.
https://doi.org/10.1158/1078-0432.CCR-07-5090
Published: 15 July 2008
View article titled, Molecular Characterization of the Pediatric Preclinical Testing Panel
Open the PDF for Molecular Characterization of the Pediatric Preclinical Testing Panel in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of VNP40101M (Cloretazine) in Children with Recurrent Brain Tumors: A Pediatric Brain Tumor Consortium Study

Sridharan Gururangan, Christopher D. Turner, Clinton F. Stewart, Melinda O'Shaughnessy, Mehmet Kocak, Tina Young Poussaint, Peter C. Phillips, Stewart Goldman, Roger Packer, Ian F. Pollack, Susan M. Blaney, Verena Karsten, Stanton L. Gerson, James M. Boyett, Henry S. Friedman, Larry E. Kun
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (4): 1124–1130.
https://doi.org/10.1158/1078-0432.CCR-07-4242
Published: 15 February 2008
View article titled, Phase I Trial of VNP40101M (Cloretazine) in Children with Recurrent Brain Tumors: A Pediatric Brain Tumor Consortium Study
Open the PDF for Phase I Trial of VNP40101M (Cloretazine) in Children with Recurrent Brain Tumors: A Pediatric Brain Tumor Consortium Study in another window
Journal Articles

Phase I Trial of Single-Dose Temozolomide and Continuous Administration of O6-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report

Alberto Broniscer, Sridharan Gururangan, Tobey J. MacDonald, Stewart Goldman, Roger J. Packer, Clinton F. Stewart, Dana Wallace, Mary K. Danks, Henry S. Friedman, Tina Y. Poussaint, Larry E. Kun, James M. Boyett, Amar Gajjar, for the Pediatric Brain Tumor Consortium
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (22): 6712–6718.
https://doi.org/10.1158/1078-0432.CCR-07-1016
Published: 15 November 2007
View article titled, Phase I Trial of Single-Dose Temozolomide and Continuous Administration of <em>O</em><sup>6</sup>-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report
Open the PDF for Phase I Trial of Single-Dose Temozolomide and Continuous Administration of <em>O</em><sup>6</sup>-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report in another window
Includes: Supplementary data
Journal Articles

Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

James J. Vredenburgh, Annick Desjardins, James E. Herndon, II, Jeannette M. Dowell, David A. Reardon, Jennifer A. Quinn, Jeremy N. Rich, Sith Sathornsumetee, Sridharan Gururangan, Melissa Wagner, Darell D. Bigner, Allan H. Friedman, Henry S. Friedman
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (4): 1253–1259.
https://doi.org/10.1158/1078-0432.CCR-06-2309
Published: 22 February 2007
View article titled, Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
Open the PDF for Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma in another window
Journal Articles

Phase I Trial of Intrathecal Spartaject Busulfan in Children with Neoplastic Meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004)

Sridharan Gururangan, William P. Petros, Tina Young Poussaint, Michael L. Hancock, Peter C. Phillips, Henry S. Friedman, Lisa Bomgaars, Susan M. Blaney, Larry E. Kun, James M. Boyett
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (5): 1540–1546.
https://doi.org/10.1158/1078-0432.CCR-05-2094
Published: 06 March 2006
View article titled, Phase I Trial of Intrathecal Spartaject Busulfan in Children with Neoplastic Meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004)
Open the PDF for Phase I Trial of Intrathecal Spartaject Busulfan in Children with Neoplastic Meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004) in another window
Journal Articles

Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma

David A. Reardon, Jennifer A. Quinn, James J. Vredenburgh, Sridharan Gururangan, Allan H. Friedman, Annick Desjardins, Sith Sathornsumetee, James E. Herndon, II, Jeannette M. Dowell, Roger E. McLendon, James M. Provenzale, John H. Sampson, Robert P. Smith, Alan J. Swaisland, Judith S. Ochs, Peggy Lyons, Sandy Tourt-Uhlig, Darell D. Bigner, Henry S. Friedman, Jeremy N. Rich
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (3): 860–868.
https://doi.org/10.1158/1078-0432.CCR-05-2215
Published: 07 February 2006
View article titled, Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma
Open the PDF for Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma in another window
Journal Articles

Optimizing a Novel Regional Chemotherapeutic Agent against Melanoma: Hyperthermia-Induced Enhancement of Temozolomide Cytotoxicity

Sae Hee Ko, Tomio Ueno, Yasunori Yoshimoto, Jin Soo Yoo, Omar I. Abdel-Wahab, Zeinab Abdel-Wahab, Edward Chu, Scott K. Pruitt, Henry S. Friedman, Mark W. Dewhirst, Douglas S. Tyler
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (1): 289–297.
https://doi.org/10.1158/1078-0432.CCR-05-0210
Published: 05 January 2006
View article titled, Optimizing a Novel Regional Chemotherapeutic Agent against Melanoma: Hyperthermia-Induced Enhancement of Temozolomide Cytotoxicity
Open the PDF for Optimizing a Novel Regional Chemotherapeutic Agent against Melanoma: Hyperthermia-Induced Enhancement of Temozolomide Cytotoxicity in another window
Journal Articles

ZD6474, a Novel Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor, Inhibits Tumor Growth of Multiple Nervous System Tumors

Jeremy N. Rich, Sith Sathornsumetee, Stephen T. Keir, Mark W. Kieran, Andrea Laforme, Arja Kaipainen, Roger E. McLendon, Michael W. Graner, B.K. Ahmed Rasheed, Ling Wang, David A. Reardon, Anderson J. Ryan, Catherine Wheeler, Isaiah Dimery, Darell D. Bigner, Henry S. Friedman
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (22): 8145–8157.
https://doi.org/10.1158/1078-0432.CCR-05-0319
Published: 18 November 2005
View article titled, ZD6474, a Novel Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor, Inhibits Tumor Growth of Multiple Nervous System Tumors
Open the PDF for ZD6474, a Novel Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor, Inhibits Tumor Growth of Multiple Nervous System Tumors in another window
Journal Articles

Resistance to Tyrosine Kinase Inhibition by Mutant Epidermal Growth Factor Receptor Variant III Contributes to the Neoplastic Phenotype of Glioblastoma Multiforme

Chris A. Learn, Tristan L. Hartzell, Carol J. Wikstrand, Gary E. Archer, Jeremy N. Rich, Allan H. Friedman, Henry S. Friedman, Darell D. Bigner, John H. Sampson
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (9): 3216–3224.
https://doi.org/10.1158/1078-0432.CCR-03-0521
Published: 06 May 2004
View article titled, Resistance to Tyrosine Kinase Inhibition by Mutant Epidermal Growth Factor Receptor Variant III Contributes to the Neoplastic Phenotype of Glioblastoma Multiforme
Open the PDF for Resistance to Tyrosine Kinase Inhibition by Mutant Epidermal Growth Factor Receptor Variant III Contributes to the Neoplastic Phenotype of Glioblastoma Multiforme in another window
Journal Articles

Efficacy of Intracerebral Microinfusion of Trastuzumab in an Athymic Rat Model of Intracerebral Metastatic Breast Cancer

Peter M. Grossi, Hidenobu Ochiai, Gary E. Archer, Roger E. McLendon, Michael R. Zalutsky, Allan H. Friedman, Henry S. Friedman, Darell D. Bigner, John H. Sampson
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (15): 5514–5520.
Published: 03 December 2003
View article titled, Efficacy of Intracerebral Microinfusion of Trastuzumab in an Athymic Rat Model of Intracerebral Metastatic Breast Cancer
Open the PDF for Efficacy of Intracerebral Microinfusion of Trastuzumab in an Athymic Rat Model of Intracerebral Metastatic Breast Cancer in another window
Journal Articles

Epidermal Growth Factor Receptor VIII Peptide Vaccination Is Efficacious against Established Intracerebral Tumors

Amy B. Heimberger, Laura E. Crotty, Gary E. Archer, Kenneth R. Hess, Carol J. Wikstrand, Allan H. Friedman, Henry S. Friedman, Darell D. Bigner, John H. Sampson
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (11): 4247–4254.
Published: 30 September 2003
View article titled, Epidermal Growth Factor Receptor VIII Peptide Vaccination Is Efficacious against Established Intracerebral Tumors
Open the PDF for Epidermal Growth Factor Receptor VIII Peptide Vaccination Is Efficacious against Established Intracerebral Tumors in another window
Journal Articles

Specific and High-Level Targeting of Radiolabeled Octreotide Analogues to Human Medulloblastoma Xenografts

Ganesan Vaidyanathan, Henry S. Friedman, Donna J. Affleck, Margaret Schottelius, Hans-Jürgen Wester, Michael R. Zalutsky
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (5): 1868–1876.
Published: 01 May 2003
View article titled, Specific and High-Level Targeting of Radiolabeled Octreotide Analogues to Human Medulloblastoma Xenografts
Open the PDF for Specific and High-Level Targeting of Radiolabeled Octreotide Analogues to Human Medulloblastoma Xenografts in another window
Journal Articles

Brain Tumors in Mice Are Susceptible to Blockade of Epidermal Growth Factor Receptor (EGFR) with the Oral, Specific, EGFR-Tyrosine Kinase Inhibitor ZD1839 (Iressa)

Amy B. Heimberger, Chris A. Learn, Gary E. Archer, Roger E. McLendon, Tracy A. Chewning, Frank L. Tuck, John B. Pracyk, Allan H. Friedman, Henry S. Friedman, Darell D. Bigner, John H. Sampson
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (11): 3496–3502.
Published: 01 November 2002
View article titled, Brain Tumors in Mice Are Susceptible to Blockade of Epidermal Growth Factor Receptor (EGFR) with the Oral, Specific, EGFR-Tyrosine Kinase Inhibitor ZD1839 (Iressa)
Open the PDF for Brain Tumors in Mice Are Susceptible to Blockade of Epidermal Growth Factor Receptor (EGFR) with the Oral, Specific, EGFR-Tyrosine Kinase Inhibitor ZD1839 (Iressa) in another window
Journal Articles

Relation between Irofulven (MGI-114) Systemic Exposure and Tumor Response in Human Solid Tumor Xenografts

Markos Leggas, Clinton F. Stewart, Michael H. Woo, Maryam Fouladi, Pamela J. Cheshire, Jennifer K. Peterson, Henry S. Friedman, Catherine Billups, Peter J. Houghton
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (9): 3000–3007.
Published: 01 September 2002
View article titled, Relation between Irofulven (MGI-114) Systemic Exposure and Tumor Response in Human Solid Tumor Xenografts
Open the PDF for Relation between Irofulven (MGI-114) Systemic Exposure and Tumor Response in Human Solid Tumor Xenografts in another window